Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Müller TD[au]:

Ghrelin. Müller TD et al. Mol Metab. (2015)

Animal models of obesity and diabetes mellitus. Kleinert M et al. Nat Rev Endocrinol. (2018)

Gut-Brain Cross-Talk in Metabolic Control. Clemmensen C et al. Cell. (2017)

Search results

Items: 1 to 50 of 112

1.

Revisiting the Pharmacological Value of Glucagon: An Editorial for the Special Issue "The Biology and Pharmacology of Glucagon".

Müller TD, Habegger K.

Int J Mol Sci. 2020 Jan 8;21(2). pii: E383. doi: 10.3390/ijms21020383.

2.

Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.

Tan Q, Orsso CE, Deehan EC, Triador L, Field CJ, Tun HM, Han JC, Müller TD, Haqq AM.

Obes Rev. 2019 Dec 30. doi: 10.1111/obr.12992. [Epub ahead of print] Review.

PMID:
31889409
3.

Gut Peptide Agonism in the Treatment of Obesity and Diabetes.

Grandl G, Novikoff A, DiMarchi R, Tschöp MH, Müller TD.

Compr Physiol. 2019 Dec 18;10(1):99-124. doi: 10.1002/cphy.c180044.

PMID:
31853954
4.

Glucagon-like peptide 1 (GLP-1).

Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH.

Mol Metab. 2019 Dec;30:72-130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30. Review.

5.

Corrigendum to "Pirt deficiency has subtle female-specific effects on energy and glucose metabolism in mice" [Molecular Metabolism 23 (2019) 75-81].

Jall S, Finan B, Collden G, Fischer K, Dong X, Tschöp MH, Müller TD, Clemmensen C.

Mol Metab. 2019 Dec;30:264. doi: 10.1016/j.molmet.2019.11.002. No abstract available.

6.

Glucagon Regulation of Energy Expenditure.

Kleinert M, Sachs S, Habegger KM, Hofmann SM, Müller TD.

Int J Mol Sci. 2019 Oct 30;20(21). pii: E5407. doi: 10.3390/ijms20215407. Review.

7.

CNS-targeting pharmacological interventions for the metabolic syndrome.

Stemmer K, Müller TD, DiMarchi RD, Pfluger PT, Tschöp MH.

J Clin Invest. 2019 Aug 5;130:4058-4071. doi: 10.1172/JCI129195. eCollection 2019 Aug 5. Review.

8.

[Incretin-based co- and tri-agonists : Innovative polypharmacology for the treatment of obesity and diabetes].

Harger A, Stemmer K, Tschöp MH, Müller TD.

Internist (Berl). 2019 Sep;60(9):895-902. doi: 10.1007/s00108-019-0649-9. Review. German.

PMID:
31346639
9.

Pirt deficiency has subtle female-specific effects on energy and glucose metabolism in mice.

Jall S, Finan B, Collden G, Fischer K, Dong X, Tschöp MH, Müller TD, Clemmensen C.

Mol Metab. 2019 May;23:75-81. doi: 10.1016/j.molmet.2019.02.011. Epub 2019 Mar 7. Erratum in: Mol Metab. 2019 Dec;30:264.

10.

Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease.

Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, Holst JJ, Knop FK, Vilsbøll T, Junker A, Sachs S, Stemmer K, Müller TD, Tschöp MH, Hofmann SM, Mann M.

Mol Syst Biol. 2019 Mar 1;15(3):e8793. doi: 10.15252/msb.20188793.

11.

Publisher Correction: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes.

Clemmensen C, Jall S, Kleinert M, Quarta C, Gruber T, Reber J, Sachs S, Fischer K, Feuchtinger A, Karlas A, Simonds SE, Grandl G, Loher D, Sanchez-Quant E, Keipert S, Jastroch M, Hofmann SM, Nascimento EBM, Schrauwen P, Ntziachristos V, Cowley MA, Finan B, Müller TD, Tschöp MH.

Nat Commun. 2018 Nov 20;9(1):4975. doi: 10.1038/s41467-018-07479-1.

12.

Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.

Clemmensen C, Finan B, Müller TD, DiMarchi RD, Tschöp MH, Hofmann SM.

Nat Rev Endocrinol. 2019 Feb;15(2):90-104. doi: 10.1038/s41574-018-0118-x. Review.

PMID:
30446744
13.

Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes.

Clemmensen C, Jall S, Kleinert M, Quarta C, Gruber T, Reber J, Sachs S, Fischer K, Feuchtinger A, Karlas A, Simonds SE, Grandl G, Loher D, Sanchez-Quant E, Keipert S, Jastroch M, Hofmann SM, Nascimento EBM, Schrauwen P, Ntziachristos V, Cowley MA, Finan B, Müller TD, Tschöp MH.

Nat Commun. 2018 Oct 23;9(1):4304. doi: 10.1038/s41467-018-06769-y. Erratum in: Nat Commun. 2018 Nov 20;9(1):4975.

14.

Peptide-based multi-agonists: a new paradigm in metabolic pharmacology.

Brandt SJ, Müller TD, DiMarchi RD, Tschöp MH, Stemmer K.

J Intern Med. 2018 Dec;284(6):581-602. doi: 10.1111/joim.12837. Epub 2018 Oct 23. Review.

PMID:
30230640
15.

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists.

Müller TD, Clemmensen C, Finan B, DiMarchi RD, Tschöp MH.

Pharmacol Rev. 2018 Oct;70(4):712-746. doi: 10.1124/pr.117.014803. Review.

PMID:
30087160
16.

An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation.

Khajavi N, Finan B, Kluth O, Müller TD, Mergler S, Schulz A, Kleinau G, Scheerer P, Schürmann A, Gudermann T, Tschöp MH, Krude H, DiMarchi RD, Biebermann H.

Cell Signal. 2018 Nov;51:13-22. doi: 10.1016/j.cellsig.2018.07.006. Epub 2018 Jul 25.

PMID:
30055232
17.

Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs.

Renner S, Blutke A, Dobenecker B, Dhom G, Müller TD, Finan B, Clemmensen C, Bernau M, Novak I, Rathkolb B, Senf S, Zöls S, Roth M, Götz A, Hofmann SM, Hrabĕ de Angelis M, Wanke R, Kienzle E, Scholz AM, DiMarchi R, Ritzmann M, Tschöp MH, Wolf E.

Mol Metab. 2018 Oct;16:180-190. doi: 10.1016/j.molmet.2018.06.015. Epub 2018 Jun 28.

18.

Circulating HDL levels control hypothalamic astrogliosis via apoA-I.

Götz A, Lehti M, Donelan E, Striese C, Cucuruz S, Sachs S, Yi CX, Woods SC, Wright SD, Müller TD, Tschöp MH, Gao Y, Hofmann SM.

J Lipid Res. 2018 Sep;59(9):1649-1659. doi: 10.1194/jlr.M085456. Epub 2018 Jul 10.

19.

A collective diabetes cross in combination with a computational framework to dissect the genetics of human obesity and Type 2 diabetes.

Vogel H, Kamitz A, Hallahan N, Lebek S, Schallschmidt T, Jonas W, Jähnert M, Gottmann P, Zellner L, Kanzleiter T, Damen M, Altenhofen D, Burkhardt R, Renner S, Dahlhoff M, Wolf E, Müller TD, Blüher M, Joost HG, Chadt A, Al-Hasani H, Schürmann A.

Hum Mol Genet. 2018 Sep 1;27(17):3099-3112. doi: 10.1093/hmg/ddy217.

20.

Are peptide conjugates the golden therapy against obesity?

Brandt SJ, Kleinert M, Tschöp MH, Müller TD.

J Endocrinol. 2018 Aug;238(2):R109-R119. doi: 10.1530/JOE-18-0264. Epub 2018 May 30. Review.

21.

Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor.

Huang J, Duran A, Reina-Campos M, Valencia T, Castilla EA, Müller TD, Tschöp MH, Moscat J, Diaz-Meco MT.

Cancer Cell. 2018 Apr 9;33(4):770-784.e6. doi: 10.1016/j.ccell.2018.03.001.

22.

The Effect of SH2B1 Variants on Expression of Leptin- and Insulin-Induced Pathways in Murine Hypothalamus.

Giuranna J, Volckmar AL, Heinen A, Peters T, Schmidt B, Spieker A, Straub H, Grallert H, Müller TD, Antel J, Haußmann U, Klafki H, Rui L, Hebebrand J, Hinney A.

Obes Facts. 2018;11(2):93-108. doi: 10.1159/000486962. Epub 2018 Apr 10. Erratum in: Obes Facts. 2018;11(3):176-180.

23.

Ghrelin regulation of glucose metabolism.

Poher AL, Tschöp MH, Müller TD.

Peptides. 2018 Feb;100:236-242. doi: 10.1016/j.peptides.2017.12.015. Review.

24.

Gut hormone polyagonists for the treatment of type 2 diabetes.

Brandt SJ, Götz A, Tschöp MH, Müller TD.

Peptides. 2018 Feb;100:190-201. doi: 10.1016/j.peptides.2017.12.021. Review.

25.

Animal models of obesity and diabetes mellitus.

Kleinert M, Clemmensen C, Hofmann SM, Moore MC, Renner S, Woods SC, Huypens P, Beckers J, de Angelis MH, Schürmann A, Bakhti M, Klingenspor M, Heiman M, Cherrington AD, Ristow M, Lickert H, Wolf E, Havel PJ, Müller TD, Tschöp MH.

Nat Rev Endocrinol. 2018 Mar;14(3):140-162. doi: 10.1038/nrendo.2017.161. Epub 2018 Jan 19. Review.

26.

Erratum. Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and HFD-Induced Obesity and Impairs the Feeding-Fasting Transition. Diabetes 2017;66:272-286.

Mueller KM, Hartmann K, Kaltenecker D, Vettorazzi S, Bauer M, Mauser L, Amann S, Jall S, Fischer K, Esterbauer H, Müller TD, Tschöp MH, Magnes C, Haybaeck J, Scherer T, Bordag N, Tuckermann JP, Moriggl R.

Diabetes. 2018 Feb;67(2):343-344. doi: 10.2337/db18-er02a. Epub 2017 Nov 16. No abstract available.

27.

The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent.

Lagler C, El-Mesery M, Kübler AC, Müller-Richter UDA, Stühmer T, Nickel J, Müller TD, Wajant H, Seher A.

PLoS One. 2017 Oct 13;12(10):e0185720. doi: 10.1371/journal.pone.0185720. eCollection 2017.

28.

Emerging Poly-Agonists for Obesity and Type 2 Diabetes.

Kleinert M, Clemmensen C, Stemmer K, Müller TD, DiMarchi RD, Tschöp MH.

Obesity (Silver Spring). 2017 Oct;25(10):1647-1649. doi: 10.1002/oby.21932. No abstract available.

29.

Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity.

Quarta C, Clemmensen C, Zhu Z, Yang B, Joseph SS, Lutter D, Yi CX, Graf E, García-Cáceres C, Legutko B, Fischer K, Brommage R, Zizzari P, Franklin BS, Krueger M, Koch M, Vettorazzi S, Li P, Hofmann SM, Bakhti M, Bastidas-Ponce A, Lickert H, Strom TM, Gailus-Durner V, Bechmann I, Perez-Tilve D, Tuckermann J, Hrabě de Angelis M, Sandoval D, Cota D, Latz E, Seeley RJ, Müller TD, DiMarchi RD, Finan B, Tschöp MH.

Cell Metab. 2017 Oct 3;26(4):620-632.e6. doi: 10.1016/j.cmet.2017.08.023. Epub 2017 Sep 21.

30.

Dual specificity phosphatase 6 deficiency is associated with impaired systemic glucose tolerance and reversible weight retardation in mice.

Pfuhlmann K, Pfluger PT, Schriever SC, Müller TD, Tschöp MH, Stemmer K.

PLoS One. 2017 Sep 5;12(9):e0183488. doi: 10.1371/journal.pone.0183488. eCollection 2017.

31.

GLP-1/glucagon receptor co-agonism for treatment of obesity.

Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH.

Diabetologia. 2017 Oct;60(10):1851-1861. doi: 10.1007/s00125-017-4354-8. Epub 2017 Jul 21. Review.

32.

Ligand-induced type II interleukin-4 receptor dimers are sustained by rapid re-association within plasma membrane microcompartments.

Richter D, Moraga I, Winkelmann H, Birkholz O, Wilmes S, Schulte M, Kraich M, Kenneweg H, Beutel O, Selenschik P, Paterok D, Gavutis M, Schmidt T, Garcia KC, Müller TD, Piehler J.

Nat Commun. 2017 Jul 14;8:15976. doi: 10.1038/ncomms15976.

33.

Utilizing BMP-2 muteins for treatment of multiple myeloma.

Seher A, Lagler C, Stühmer T, Müller-Richter UDA, Kübler AC, Sebald W, Müller TD, Nickel J.

PLoS One. 2017 May 10;12(5):e0174884. doi: 10.1371/journal.pone.0174884. eCollection 2017.

34.

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.

Jall S, Sachs S, Clemmensen C, Finan B, Neff F, DiMarchi RD, Tschöp MH, Müller TD, Hofmann SM.

Mol Metab. 2017 Mar 1;6(5):440-446. doi: 10.1016/j.molmet.2017.02.002. eCollection 2017 May.

35.

Alternatively activated macrophages do not synthesize catecholamines or contribute to adipose tissue adaptive thermogenesis.

Fischer K, Ruiz HH, Jhun K, Finan B, Oberlin DJ, van der Heide V, Kalinovich AV, Petrovic N, Wolf Y, Clemmensen C, Shin AC, Divanovic S, Brombacher F, Glasmacher E, Keipert S, Jastroch M, Nagler J, Schramm KW, Medrikova D, Collden G, Woods SC, Herzig S, Homann D, Jung S, Nedergaard J, Cannon B, Tschöp MH, Müller TD, Buettner C.

Nat Med. 2017 May;23(5):623-630. doi: 10.1038/nm.4316. Epub 2017 Apr 17.

36.

Therapeutic Potential of Targeting the Ghrelin Pathway.

Colldén G, Tschöp MH, Müller TD.

Int J Mol Sci. 2017 Apr 11;18(4). pii: E798. doi: 10.3390/ijms18040798. Review.

37.

The New Biology and Pharmacology of Glucagon.

Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH.

Physiol Rev. 2017 Apr;97(2):721-766. doi: 10.1152/physrev.00025.2016. Review.

38.

Gut-Brain Cross-Talk in Metabolic Control.

Clemmensen C, Müller TD, Woods SC, Berthoud HR, Seeley RJ, Tschöp MH.

Cell. 2017 Feb 23;168(5):758-774. doi: 10.1016/j.cell.2017.01.025. Review.

39.

Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.

Finan B, Clemmensen C, Zhu Z, Stemmer K, Gauthier K, Müller L, De Angelis M, Moreth K, Neff F, Perez-Tilve D, Fischer K, Lutter D, Sánchez-Garrido MA, Liu P, Tuckermann J, Malehmir M, Healy ME, Weber A, Heikenwalder M, Jastroch M, Kleinert M, Jall S, Brandt S, Flamant F, Schramm KW, Biebermann H, Döring Y, Weber C, Habegger KM, Keuper M, Gelfanov V, Liu F, Köhrle J, Rozman J, Fuchs H, Gailus-Durner V, Hrabě de Angelis M, Hofmann SM, Yang B, Tschöp MH, DiMarchi R, Müller TD.

Cell. 2016 Oct 20;167(3):843-857.e14. doi: 10.1016/j.cell.2016.09.014. Epub 2016 Oct 6.

40.

Fibroblast activation protein (FAP) as a novel metabolic target.

Sánchez-Garrido MA, Habegger KM, Clemmensen C, Holleman C, Müller TD, Perez-Tilve D, Li P, Agrawal AS, Finan B, Drucker DJ, Tschöp MH, DiMarchi RD, Kharitonenkov A.

Mol Metab. 2016 Jul 16;5(10):1015-1024. doi: 10.1016/j.molmet.2016.07.003. eCollection 2016 Oct.

41.

Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and HFD-Induced Obesity and Impairs the Feeding-Fasting Transition.

Mueller KM, Hartmann K, Kaltenecker D, Vettorazzi S, Bauer M, Mauser L, Amann S, Jall S, Fischer K, Esterbauer H, Müller TD, Tschöp MH, Magnes C, Haybaeck J, Scherer T, Bordag N, Tuckermann JP, Moriggl R.

Diabetes. 2017 Feb;66(2):272-286. doi: 10.2337/db16-0381. Epub 2016 Sep 20. Erratum in: Diabetes. 2017 Nov 16;:.

42.

Determination of thyroid hormones in mouse tissues by isotope-dilution microflow liquid chromatography-mass spectrometry method.

De Angelis M, Giesert F, Finan B, Clemmensen C, Müller TD, Vogt-Weisenhorn D, Tschöp MH, Schramm KW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:413-420. doi: 10.1016/j.jchromb.2016.08.037. Epub 2016 Aug 26.

PMID:
27649501
43.

Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion.

Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, Vaeth M, Kuen J, Holtappels R, Podlech J, Mottok A, Kraus S, Jordán-Garrote AL, Bäuerlein CA, Brede C, Ribechini E, Fick A, Seher A, Polz J, Ottmüller KJ, Baker J, Nishikii H, Ritz M, Mattenheimer K, Schwinn S, Winter T, Schäfer V, Krappmann S, Einsele H, Müller TD, Reddehase MJ, Lutz MB, Männel DN, Berberich-Siebelt F, Wajant H, Beilhack A.

J Exp Med. 2016 Aug 22;213(9):1881-900. doi: 10.1084/jem.20151563. Epub 2016 Aug 15.

44.

Evidence for three genetic loci involved in both anorexia nervosa risk and variation of body mass index.

Hinney A, Kesselmeier M, Jall S, Volckmar AL, Föcker M, Antel J; GCAN, WTCCC3, Heid IM, Winkler TW; GIANT, SFA Grant, EGG, Guo Y, Bergen AW, Kaye W, Berrettini W, Hakonarson H; Price Foundation Collaborative Group, Children’s Hospital of Philadelphia/Price Foundation, Herpertz-Dahlmann B, de Zwaan M, Herzog W, Ehrlich S, Zipfel S, Egberts KM, Adan R, Brandys M, van Elburg A, Boraska Perica V, Franklin CS, Tschöp MH, Zeggini E, Bulik CM, Collier D, Scherag A, Müller TD, Hebebrand J.

Mol Psychiatry. 2017 Feb;22(2):321-322. doi: 10.1038/mp.2016.126. Epub 2016 Jul 26. No abstract available.

PMID:
27457816
45.

Metabolic Precision Medicines: Curing POMC Deficiency.

Müller TD, Tschöp MH, O'Rahilly S.

Cell Metab. 2016 Aug 9;24(2):194-5. doi: 10.1016/j.cmet.2016.07.006. Epub 2016 Jul 21.

46.

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.

Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD, DiMarchi RD.

Cell Metab. 2016 Jul 12;24(1):51-62. doi: 10.1016/j.cmet.2016.06.021. Review.

47.

Ghrelin modulates encoding-related brain function without enhancing memory formation in humans.

Kunath N, Müller NCJ, Tonon M, Konrad BN, Pawlowski M, Kopczak A, Elbau I, Uhr M, Kühn S, Repantis D, Ohla K, Müller TD, Fernández G, Tschöp M, Czisch M, Steiger A, Dresler M.

Neuroimage. 2016 Nov 15;142:465-473. doi: 10.1016/j.neuroimage.2016.07.016. Epub 2016 Jul 9.

PMID:
27402596
48.

Evidence for three genetic loci involved in both anorexia nervosa risk and variation of body mass index.

Hinney A, Kesselmeier M, Jall S, Volckmar AL, Föcker M, Antel J; GCAN; WTCCC3, Heid IM, Winkler TW; GIANT, Grant SF; EGG, Guo Y, Bergen AW, Kaye W, Berrettini W, Hakonarson H; Price Foundation Collaborative Group; Children’s Hospital of Philadelphia/Price Foundation, Herpertz-Dahlmann B, de Zwaan M, Herzog W, Ehrlich S, Zipfel S, Egberts KM, Adan R, Brandys M, van Elburg A, Boraska Perica V, Franklin CS, Tschöp MH, Zeggini E, Bulik CM, Collier D, Scherag A, Müller TD, Hebebrand J.

Mol Psychiatry. 2017 Feb;22(2):192-201. doi: 10.1038/mp.2016.71. Epub 2016 May 17. Erratum in: Mol Psychiatry. 2017 Feb;22(2):321-322.

49.

Identification of GPR83 as the receptor for the neuroendocrine peptide PEN.

Gomes I, Bobeck EN, Margolis EB, Gupta A, Sierra S, Fakira AK, Fujita W, Müller TD, Müller A, Tschöp MH, Kleinau G, Fricker LD, Devi LA.

Sci Signal. 2016 Apr 26;9(425):ra43. doi: 10.1126/scisignal.aad0694.

50.

Reappraisal of GIP Pharmacology for Metabolic Diseases.

Finan B, Müller TD, Clemmensen C, Perez-Tilve D, DiMarchi RD, Tschöp MH.

Trends Mol Med. 2016 May;22(5):359-376. doi: 10.1016/j.molmed.2016.03.005. Epub 2016 Mar 30. Review.

PMID:
27038883

Supplemental Content

Loading ...
Support Center